Brand Name | Status | Last Update |
---|---|---|
actemra | Biologic Licensing Application | 2018-10-01 |
actemra actemra actpen | Biologic Licensing Application | 2024-11-06 |
avtozma | Biologic Licensing Application | 2025-01-31 |
tocilizumab-anoh | Biologic Licensing Application | 2025-01-31 |
tofidence | Biologic Licensing Application | 2025-03-17 |
tyenne | Biologic Licensing Application | 2024-12-30 |
Expiration | Code | ||
---|---|---|---|
tocilizumab, Actemra, Genentech, Inc. | |||
2028-03-04 | Orphan excl. | ||
2024-08-30 | Orphan excl. |
Code | Description |
---|---|
J3262 | Injection, tocilizumab, 1 mg |
M0249 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose |
M0250 | Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, second dose |
Q0249 | Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Tocilizumab |
INN | tocilizumab |
Description | Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. It was developed by Hoffmann–La Roche and Chugai.
|
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL1237022 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB06273 |
UNII ID | I031V2H011 (ChemIDplus, GSRS) |